Oxford BioMedica (LSE: OXB), the leading gene therapy company, today announces that, with immediate effect, Dr Mike McDonald has been promoted to the Board as an executive director. He will maintain his title of Chief Medical Officer. His primary responsibilities include the Company’s clinical development activities and regulatory affairs.
